<img src="https://salesviewer.org/k6a5l3V9y8O3.gif" style="visibility:hidden;">

FCF Healthcare & Life Sciences Venture Capital Monitor – Europa – 06/2023 published

1 min read
Jul 17, 2023 8:00:00 AM
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of June 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 4,865m
  • Biotech received 47% of the total investment volume (+2% compared to the previous month)
  • Oncology dominates as the top indication in Biotechnology
  • Ellipses Pharma (United Kingdom) has the highest transaction volume of EUR 126m in June, followed by Beacon Therapeutics (United Kingdom) EUR 111m and Corwave (France) EUR 61m 
  • Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by European Innovation Council Fund (Belgium) and Gilde Healthcare Partners (Netherlands)
  • Top 5 Deals exceed EUR 120m each, the largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.